CMS Open Payments · Program Year 2024
Mylan Specialty L.P.
Mylan Specialty L.P. reported $2,914,755.77 across General Payments, Research, and Ownership to 29,055 physicians and teaching hospitals across 29,170 transactions.
- $2.9M Top quartile payer
- All-tracks total
- 29,170 Top 10% volume
- Transactions
- 29,055 Top 10% reach
- Recipients
- −$49.5K
- General Payments vs PY2023
Mylan Specialty L.P. reported $2,914,755.77 across all CMS Open Payments tracks (General + Research + Ownership) to 29,055 physicians and teaching hospitals in Program Year 2024 - ranking #370 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,385,494.05, averaging $100.32 per recipient.
How Mylan Specialty L.P.'s $2.9M all-tracks total breaks down
Mylan Specialty L.P.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
79/100
Total payments
F
37/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mylan-specialty-l-p Mylan Specialty L.P.
$2.9M · #370/1,925 · 0.0% industry · PY2024
- TOT $2.9M
- RANK #370
- SHARE 0.0%
- TXN 29,170
- RCP 29,055
- CAT 6
- GEN $1.4M
- ΔGEN −$49.5K
- TOP1 2.6%
- PY 2024
Volume peers
Nearest volume peer: Senseonics, Incorporated ($2.9M)
Mylan Specialty L.P. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Mylan Specialty L.P.'s CMS-reported General Payments decreased by $49.5K (−3.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MYLAN SPECIALTY L.P.PY2023: MYLAN SPECIALTY L.P.PY2024: Mylan Specialty L.P.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,435,006.79
- PY2024
- $1,385,494.05
What the Data Shows for Mylan Specialty L.P.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Mylan Specialty L.P., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 6-category general-payment breakdown below at $660.9K (47.7% of General Payments, 28,257 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Mylan Specialty L.P. made 6 types of general payments. "Food and Beverage" is the largest category at $660.9K, 47.7% of General Payments.
Mylan Specialty L.P. reports 6 general-payment categories - the top three are Food and Beverage (47.7%), Compensation for Services Other Than Consulting (40.1%), and Consulting Fee (6.5%). The remaining 3 categories make up 5.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Mylan Specialty L.P. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $660.9K | 28,257 | 47.7% |
| Compensation for Services Other Than Consulting | $555.7K | 399 | 40.1% |
| Consulting Fee | $90.6K | 24 | 6.5% |
| Travel and Lodging | $52.4K | 205 | 3.8% |
| Space Rental or Facility Fees | $22.2K | 13 | 1.6% |
| Education | $3.6K | 157 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $131,932.58 (9.5%) of $1,385,494.05 in this company's General Payments records across 12,268 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Mylan Specialty L.P.
The five named recipients with the highest reported General Payments from this company
- 1
Tarun Madappa
$35,432.16 across 40 reported transactions
- 2
Sandra Schuldheisz
$26,017.65 across 45 reported transactions
- 3
Jeffrey Wolf
$25,577.16 across 41 reported transactions
- 4
Lacey Kristin Matheis
$22,952.97 across 40 reported transactions
- 5
William Alleyne
$21,952.64 across 17 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Mylan Specialty L.P. ranks #370 of 1,925 by total payments (top 19% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,760 of 1,838 by HHI (bottom 4% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- EMD Serono, Inc. : $10.0M total payments, HHI 58
- Abbvie Inc. : $156.7M total payments, HHI 57
- Journey Medical Corporation : $64.6K total payments, HHI 55
- Eisai Inc. : $7.1M total payments, HHI 55
- Amgen Inc. : $44.9M total payments, HHI 55
- ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) : $10.8M total payments, HHI 52
- Mylan Specialty L.P. (this company) : $1.4M total payments, HHI 51
- Virtus Pharmaceuticals LLC : $19.8K total payments, HHI 50
- Madrigal Pharmaceuticals : $4.5M total payments, HHI 49
- Electronic Waveform Lab, Inc. : $32.0K total payments, HHI 47
- Avvisto Therapeutics, LLC : $8.9K total payments, HHI 47
- Neurocrine Biosciences, Inc. : $14.2M total payments, HHI 47
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Mylan Specialty L.P.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Mylan Specialty L.P..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Mylan Specialty L.P..
Showing 6 of 1,924 companies with CMS-reported payment data.
Cortex, Inc.
Instrumentation Laboratory Company
Mirum Pharmaceuticals, Inc.
Vitalant
CathWorks, Inc.
Put this to use
Mylan Specialty L.P. ranks #370 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Mylan Specialty L.P. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Mylan Specialty L.P.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.